Management Team

NKMAX

NKMAX is headquartered in South Korea and was founded in 2002. The company's biological research reagents are currently solely distributed by headquarters in South Korea. An executive staff including CEO, Sangwoo Park, leads NKMAX and its divisions in Canada and the United States.

 

Sangwoo Park

Chief Executive Officer

After working at Samsung Securities as a financial analyst in a fund management team specialized in the biotech industry for several years, Mr. Park founded NKMAX. Since then, he has fully dedicated himself to its success by bringing thousands of proteins and antibodies to the research market and a diagnostic test that will have a significant impact in the medical community. He has seen his company grow from 2 to over 75 employees in working in three offices worldwide. He is about improving the life of people everywhere.

 

Yonghwan Cho

Executive Managing Director

B.S. Business Admin. Korea Univ.

Department of Health and Human Services, Ministry of Government Administration and Home Affairs

 

Pierre Gagnon

International Marketing Director

Mr. Gagnon joined NKMAX in 2008 where his diversified work experience in finance and education helped propel NKMAX to international markets. He is involved in several aspects of NKMAX’s policies, objectives, and initiatives. He helps guide operations abroad in accordance to headquarter’s directives. He has also been in charge of setting up subsidiaries abroad and help develop international marketing strategies.

 

Jongsun Kim, Ph.D.

Nonexecutive Director
Caltech PhD, Medical Professor at Yonsei University

 

 

Jaemyun Lee, M.D.

Nonexecutive Director
Yonsei Univ. PhD, Medicine, Medical Professor at Yonsei University

 

 

Paul Y. Song, M.D.

Chief Medical Officer and Expert Advisor of NKMAX

Paul Y. Song, M.D., is currently overseeing NKMAX’s clinical trials in the U.S. and in Denmark, while promoting the importance of NK Cell activity in the medical community internationally.

He is on the faculty at the Samuel Oschin Cancer Center at Cedars Sinai Medical Center in the department of radiation oncology. Dr. Song is also a Senior Adviser/minority shareholder at Berg Pharma, where he previously served as its Chief Medical Officer for the company’s first four years. His late grandfather, Sang Don Kim, was the first popularly elected Mayor of Seoul, South Korea.

Dr. Song graduated with honors from the University of Chicago and received his M.D. degree from George Washington University. He completed his residency in radiation oncology at the University of Chicago and did a brachytherapy fellowship at the Institute Gustave Roussy in Villejuif, France. Dr. Song received a research fellowship grant by the American Society of Therapeutic Radiation and Oncology for his work in genetic radiotherapy.

He served as a visiting fellow on healthcare policy in the California Department of Insurance in 2014. He lives in Santa Monica with his wife, Lisa and their daughter Jett.

 

 

 

0